---
title: "SeaStar Medical | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 615 K"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295706033.md"
datetime: "2026-08-12T20:30:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295706033.md)
  - [en](https://longbridge.com/en/news/295706033.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295706033.md)
generator: "portal-rs"
---

# SeaStar Medical | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 615 K

Revenue: As of FY2026 Q2, the actual value is USD 615 K, beating the estimate of USD 486.5 K.

EPS: As of FY2026 Q2, the actual value is USD -0.91, beating the estimate of USD -0.97.

EBIT: As of FY2026 Q2, the actual value is USD -3.722 M.

#### Financial and Operational Metrics

The provided reference, a Form 8-K filing by SeaStar Medical Holding Corporation, dated August 12, 2026, explicitly states that actual financial and operational metrics, including revenue, net income, gross margin, operating profit, cash flow, or any forward-looking guidance, are not contained within the provided text of this Form 8-K.

### Related Stocks

- [ICU.US](https://longbridge.com/en/quote/ICU.US.md)

## Related News & Research

- [SeaStar Medical CFO Michael Messinger acquires 750 common shares worth $2,452.5](https://longbridge.com/en/news/296396582.md)
- [SeaStar Medical Q2 revenue jumps 82% on QUELIMMUNE demand](https://longbridge.com/en/news/295705119.md)
- [Skye Bio amends 8-K to set Aug. 24 effective date for reverse stock split](https://longbridge.com/en/news/296471274.md)
- [Vital Farms amends 8-K to add missing Item 5.03 in EDGAR header](https://longbridge.com/en/news/296122466.md)
- [Valion Bio amends 8-K to report final vote tally on reverse stock split approval](https://longbridge.com/en/news/296531983.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**